Cortexin

Cortexin is a water-soluble fraction of bovine cortex proteins, standardised by peptide content rather than by any identified active molecule. The manufacturer's proposed mechanism is normalisation of the glutamate-to-GABA balance, reduction of free-radical damage to neurons, and a general neurotrophic effect on cortical tissue. Russian studies report improvements in EEG measures and cognitive scales in encephalopathy and post-stroke cohorts. As with Cerebrolysin, no specific active peptide has ever been isolated and no mechanism has been confirmed outside the manufacturer's own literature, so the mechanistic account should be read as a hypothesis rather than a finding.

Targets: Glutamate/GABA balance (proposed), Neuronal oxidative stress (proposed), Cortical neurotrophic signalling (proposed)

• · A 10 mg vial is reconstituted in 1-2 mL and injected intramuscularly. Courses are repeated after 3-6 months if used chronically.
• · 5 mg for children under 20 kg, 10 mg above. Listed for completeness because this is a large part of its actual clinical use in Russia, not as a recommendation.

Work out your exact syringe units →

• commonInjection-site pain— The reason procaine is often used as the diluent.
• uncommonInsomnia or overstimulation— Mostly with evening dosing.
• uncommonHeadache
• rareHypersensitivity reaction to bovine protein— This is a parenterally administered bovine brain extract. That risk is not zero and is the main reason regulators outside Russia will not touch it.

• Known hypersensitivity to Cortexin or to bovine protein.
• Pregnancy - contraindicated on the Russian label.
• Allergy to procaine if using procaine as the diluent - use saline instead.

• redundantcerebrolysin — Both are mammalian brain-derived peptide extracts for the same indications. Pick one.
• synergysemax — Commonly combined in Russian neurology courses for post-stroke recovery.

• · Watch the first injection for hypersensitivity.
• · No routine bloodwork is established.

Registered prescription medicine in Russia and several CIS countries. Not approved anywhere in the West, and importing an injectable bovine brain extract is a customs problem in most jurisdictions.

The mechanistic account here needs to be labelled for what it is, which is a manufacturer's hypothesis rather than a set of findings. The proposed actions - normalisation of the glutamate-to-GABA balance, reduction of free-radical damage to neurons, and a general cortical neurotrophic effect - are the same three claims made for most brain hydrolysates, and none of them has been demonstrated with an identified molecule or an independently replicated experiment. What exists is a body of Russian clinical reporting describing EEG changes and improvements on cognitive scales in encephalopathy, post-stroke and paediatric developmental cohorts. Searching the indexed international literature for Cortexin returns almost nothing that would qualify as a controlled trial - the papers that come up are reviews of neuropeptides in cerebrovascular disease, epigenetic-mechanism speculation from the Khavinson lineage, and small open-label reports such as its use as an adjunct in post-stroke epilepsy. That is the honest state of the evidence. Structurally, Cortexin sits alongside Cerebrolysin - a mammalian brain hydrolysate with no identified active principle - but with a fraction of the trial evidence and none of the independent Cochrane scrutiny. Where Cerebrolysin's problem is that thousands of randomised patients produced an ambiguous answer, Cortexin's problem is that nobody has run the trial that would produce an answer at all.

The injection hurts, which is why procaine is traditionally used as the diluent - and procaine introduces its own allergy risk, so anyone with a caine-anaesthetic sensitivity should use saline and accept the sting. Foaming during reconstitution denatures the peptide fraction, so the diluent goes down the vial wall slowly and the vial is swirled rather than shaken. The reconstituted solution has no preservative and is not intended to be stored - it is a same-day product regardless of what is convenient. Evening dosing disturbs sleep in a meaningful fraction of users. But the failure that matters is the one that gets ignored: this is an injectable bovine brain extract, sensitisation builds across repeated courses, and anaphylaxis to a heterologous protein is a genuinely serious event. Importing it is also a customs problem in most Western jurisdictions specifically because of what it is made from. The other quiet failure is evaluative - a 10-day unblinded injection course with a Russian clinical tradition behind it is an almost perfect placebo delivery system, and without a baseline instrument you will not be able to tell.

• Glutamate / GABA balance — Not applicable - no identified ligand, no binding data

  Proposed normalisation of excitatory-inhibitory balance. Asserted by the manufacturer, not demonstrated.

• Neuronal oxidative stress — Not applicable

  Proposed reduction of free-radical injury to neurons. Reported in Russian literature; not independently replicated.

• Cortical neurotrophic signalling — Not applicable

  Proposed general neurotrophic effect on cortical tissue. This is the least specific of the three claims and the hardest to test.

Nothing acute. The standard course is 10 consecutive daily intramuscular injections and benefits, where claimed, are assessed at the end of it. Courses are repeated no more often than every 3-6 months. There is no published timecourse data of any kind because there is no pharmacokinetic study - the 10-day course length is convention from Russian clinical practice rather than a derived schedule.

Running Cortexin alongside Cerebrolysin is duplication with extra allergen exposure - both are mammalian brain hydrolysates with unidentified active principles aimed at the same indications, one bovine and one porcine, and there is no reason to think they do different things. Pick one, and if you are picking on evidence, pick the one with randomised trials. The standard Russian neurology combination is Cortexin with Semax for post-stroke recovery, which has tradition behind it and no trial data. Cortagen is marketed as the synthetic tetrapeptide counterpart of this exact extract, so running both is duplication of intent by the manufacturer's own framing. The genuinely important note is not pharmacological: if you are sensitised to bovine protein from a previous course, no stack matters, and cumulative exposure to a heterologous protein across repeated annual courses is the risk that actually accumulates here.

Against Cerebrolysin, its direct analogue: same category of product, bovine instead of porcine, same absence of an identified active molecule - and a fraction of the evidence. Cerebrolysin has CASTA with 1070 randomised patients, CARS, and two independent Cochrane reviews. Cortexin has open-label Russian reports and a long clinical tradition. If you have decided you want a brain hydrolysate, the evidential argument for Cerebrolysin over Cortexin is not close, though Cerebrolysin's own evidence is genuinely mixed. Against Cortagen: Cortagen is the synthetic tetrapeptide counterpart of this extract from the Khavinson programme, with the advantage of being a defined molecule and the disadvantage of an even thinner evidence base. Against Semax: Semax is self-administrable, needle-free, cheap and has an actual registered indication with a published human study behind it. For a consumer weighing a cognitive peptide, the case for injecting a bovine brain extract over an intranasal synthetic heptapeptide is difficult to make on any axis - evidence, safety, convenience or legality. The strongest honest argument for Cortexin is that it has decades of routine paediatric and adult neurological use in Russia without a documented pattern of serious harm, which is real-world safety data of a sort.

$60–$180/month. A box of ten 10 mg vials typically runs 50-120 USD from Russian or CIS pharmacy sources, which is exactly one standard course. Since courses are repeated only every 3-6 months, the annualised cost is modest, but the per-course cost plus the difficulty and legal risk of importing it are the real barriers rather than the price.

• ?No active molecular species has ever been identified in Cortexin.
• ?No pharmacokinetic data exists of any kind - not tmax, half-life, distribution, clearance or brain penetration.
• ?Whether any component crosses the blood-brain barrier after intramuscular injection has never been demonstrated.
• ?The proposed glutamate/GABA, antioxidant and neurotrophic mechanisms are manufacturer claims without independent experimental support.
• ?I could not locate a single randomised placebo-controlled trial of Cortexin in the indexed international literature.
• ?The rate of hypersensitivity reactions across repeated courses is not documented anywhere I could find, which for a heterologous protein preparation is a significant gap.
• ?Batch-to-batch consistency of an extract standardised by peptide content rather than by identified molecule is not independently verifiable.
• ?The 10-day course length and the 3-6 month repeat interval are clinical convention with no dose-finding study behind them.
• ?Whether the modern product carries any residual risk relating to bovine central nervous tissue sourcing is not something I could establish from public documentation.

• Cortexin in the complex treatment of post-stroke epilepsy Gafurov BG, Gafurov ShB, Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2010 · PMID 20873481

  One of the few Cortexin papers indexed internationally. An open-label adjunct study - included as further reading and as an illustration of the quality level of the available literature, not as evidence of efficacy.

• Clinical efficacy of neuropeptides in cerebrovascular pathology Shavlovskaya OA, Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2016 · PMID 28635743

  A Russian review situating Cortexin among the neuropeptide preparations used in cerebrovascular disease. Useful for understanding how the compound is positioned clinically in Russia; not an independent efficacy assessment.